3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
Interventions
Filgrastim
9
Cytarabine
9
fludarabine phosphate
7
Peripheral Blood Stem Cell Transplantation
7
Mycophenolic Acid
6
Whole-Body Irradiation
5
Granulocyte Colony-Stimulating Factor
5
Cladribine
5
Mitoxantrone
4
Methotrexate
4
Cyclophosphamide
4
Melphalan
3
Injections
3
Cyclosporine
3
Biopsy
3
venetoclax
2
revumenib
2
pegylated granulocyte colony-stimulating factor
2
X-Rays
2
Trimethoprim, Sulfamethoxazole Drug Combination
2
Tacrolimus
2
Specimen Handling
2
Idarubicin
2
Decitabine
2
Daunorubicin
2
Clofarabine
2
Busulfan
2
Bone Marrow Transplantation
2
quizartinib
1
merphos
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Leukemia, Biphenotypic, Acute
×
Cobicistat
×
Clear all
NCT04065399
2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2
Recruiting
447 enrolled
2 FDA